VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics


VYNE Therapeutics Inc. (VYNE): $0.25

0.01 (+2.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VYNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VYNE Stock Summary

  • With a year-over-year growth in debt of -99.91%, VYNE THERAPEUTICS INC's debt growth rate surpasses only 1.22% of about US stocks.
  • Revenue growth over the past 12 months for VYNE THERAPEUTICS INC comes in at -58.06%, a number that bests only 3.05% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VYNE comes in at 246.09% -- higher than that of 98.73% of stocks in our set.
  • Stocks that are quantitatively similar to VYNE, based on their financial statements, market capitalization, and price volatility, are WISA, AAOI, MRIN, EYPT, and IPGP.
  • Visit VYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.menlotherapeutics.com.

VYNE Valuation Summary

  • VYNE's price/sales ratio is 2.1; this is 10.53% higher than that of the median Healthcare stock.
  • VYNE's EV/EBIT ratio has moved up 43.5 over the prior 57 months.

Below are key valuation metrics over time for VYNE.

Stock Date P/S P/B P/E EV/EBIT
VYNE 2022-09-23 2.1 0.3 -0.4 0.9
VYNE 2022-09-22 2.1 0.3 -0.4 0.9
VYNE 2022-09-21 2.2 0.3 -0.4 0.8
VYNE 2022-09-20 2.3 0.3 -0.4 0.8
VYNE 2022-09-19 2.3 0.3 -0.4 0.8
VYNE 2022-09-16 2.4 0.3 -0.4 0.8

VYNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
  • VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VYNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.856 -2.324
2021-03-31 0.194 0.926 -5.086
2020-12-31 0.170 0.934 -4.672
2020-09-30 0.140 0.949 -4.901
2020-06-30 0.115 0.964 -4.606
2020-03-31 0.016 0.845 -1.853

VYNE Price Target

For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.58 (Moderate Buy)

VYNE Stock Price Chart Interactive Chart >

Price chart for VYNE

VYNE Price/Volume Stats

Current price $0.25 52-week high $1.75
Prev. close $0.24 52-week low $0.22
Day low $0.24 Volume 62,715
Day high $0.27 Avg. volume 660,651
50-day MA $0.31 Dividend yield N/A
200-day MA $0.52 Market Cap 14.33M

VYNE Therapeutics Inc. (VYNE) Company Bio


VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.


VYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

VYNE Latest Social Stream


Loading social stream, please wait...

View Full VYNE Social Stream

Latest VYNE News From Around the Web

Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.

VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 13, 2022BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Manageme

Yahoo | September 6, 2022

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. "We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to co

Yahoo | August 12, 2022

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and MiNK Therapeutics (INKT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VYNE Therapeutics (VYNE – Research Report) and MiNK Therapeutics (INKT – Research Report) with bullish sentiments. VYNE Therapeutics (VYNE) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on VYNE Therapeutics, with a price target of $1.50. The company's shares closed last Wednesday at $0.26. According to TipRanks.

Howard Kim on TipRanks | August 10, 2022

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). Study VY2021-01 did not meet its primary endpoint based on the absolute

Yahoo | August 10, 2022

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022. B&T Cell-Mediated Autoimmune Disease Dru

Yahoo | July 19, 2022

Read More 'VYNE' Stories Here

VYNE Price Returns

1-mo N/A
3-mo -45.69%
6-mo -57.76%
1-year -78.99%
3-year -98.57%
5-year N/A
YTD -75.49%
2021 -83.86%
2020 -65.95%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6326 seconds.